We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sesen Bio Inc | NASDAQ:SESN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.6288 | 0.6005 | 0.629 | 0 | 01:00:00 |
From May 2021 to May 2024
By Josh Beckerman
Sesen Bio Inc. shares were recently down 35% to $1.37, following a 57% decline on Friday when the company received a rejection letter from the U.S. Food and Drug Administration for its Biologics License Application for lead product candidate Vicineum.
On Monday, HC Wainwright downgraded Sesen to neutral from buy.
Vicineum is being developed for the treatment of BCG-unresponsive non-muscle invasive bladder cancer.
Sesen shares were below $1.50 at the beginning of the year. In recent months, Sesen said it remained on track for potential FDA approval in August.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
August 16, 2021 12:52 ET (16:52 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sesen Bio Chart |
1 Month Sesen Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
